Results of ASM 2021

MEETING
Fri, Aug 06 2021 02:13 pm

6 August 2021
Results of 2021 Annual Shareholder Meeting

At AFT Pharmaceuticals Limited’s (NZX: AFT / ASX: AFP) annual shareholder meeting held at the Milford Cruising Club, 24 Craig Road, Milford, Auckland, New Zealand today, shareholders were asked to vote on two resolutions, both of which were supported by the Board.

As required by NZX Listing Rule 6.1, all voting was conducted by a poll.

The resolutions passed by shareholders were:

1. That the directors are authorised to fix the fees and expenses of Deloitte as auditor for the 2022 financial year.

2. That Mr David Flacks be re-elected as a director of AFT Pharmaceuticals Limited.

3. That Ms Anita Baldauf be elected as a director of AFT Pharmaceuticals Limited.

4. That Dr Ted Witek be elected as a director of AFT Pharmaceuticals Limited.

Detail of the total number of votes cast in person or by a proxy holder are:

Resolution For Against Abstain

1. That the directors are authorised to fix the fees and expenses of Deloitte as auditor for the 2022 financial year.
85,556,390
99.99%
11,972
0.01%

-



2. That Mr David Flacks be re-elected as a director of AFT Pharmaceuticals Limited.
85,563,187
99.99% 5,195
0.01% -


3. That Ms Anita Baldauf be elected as a director of AFT Pharmaceuticals Limited.
85,565,716
100.00% 2,646
0.00% -

4. That Dr Ted Witek be elected as a director of AFT Pharmaceuticals Limited.
85,567,067
100.00% 1,295
0.00% -

Authority for this announcement
Name of person authorised to make this announcement Malcolm Tubby, Chief Financial Officer
Contact person for this announcement Malcolm Tubby
Contact phone number +64 9 488 0232
Contact email address [email protected]

Date of release through MAP 6 August 2021





Announcement PDF


Markets News

NZ shares spring into September on hopes of economic revival
Markets Market close

NZ shares spring into September on hopes of economic revival

The S&P/NZX 50 Index advanced 107.84 points, or 0.9%, to 12,555.52.

Property

Ryman outlines plan to get ‘Fit for the Future’

A new pricing regime comes as the company seeks amendments to loan covenants.

Ryman outlines plan to get ‘Fit for the Future’
Markets

Simon Herbert fires salvo at Vital: 'It needs new direction'

Herbert unimpressed by Vital's refusal for due diligence and failure to meet guidance.

Simon Herbert fires salvo at Vital: 'It needs new direction'